Photodynamic therapy with verteporfin for corneal neovascularization.
Photodynamic therapy with verteporfin for corneal neovascularization.
复制标题
DOI：
10.4103/0974-9233.95246
复制
发表时间：
2012-04
影响因子：
0.6
通讯作者：
Al-Torbak AA
中科院分区：
文献类型：
--
作者：
Al-Torbak AA
探讨维替泊芬光动力疗法治疗角膜新生血管的疗效。回顾性研究了2007年1月1日至2009年12月30日期间，沙特阿拉伯利雅得国王哈立德眼科专科医院33眼32例常规治疗难治性角膜新生血管稳定患者，采用维托泊芬（6mg /m2）单次光动力治疗。平均年龄40.7±19岁（16 ~ 76岁）。所有患者的平均随访时间为13.1±5.5个月（6-24个月）。角膜新生血管平均2.7±1.9（1-10）个。角膜新生血管19眼（57.6%）深，14眼（42.4%）浅。观察术前、术后视力、眼压及临床疗效。统计分析与潜在危险因素的关系，评估数据的变化，确定失败的风险。p值小于0.05有统计学意义。最后一次随访时，22只（66.7%）眼出现角膜新生血管减少和血管血栓形成的迹象。血管完全闭塞14眼（42.4%），部分闭塞8眼（24.2%），血管通畅11眼（33.3%）。角膜新生血管评分和血管深度是手术失败的重要危险因素（P值分别为0.0001和0.046）。然而，角膜新生血管的诊断或原因没有统计学意义。未观察到与光动力治疗相关的明显的全身或眼部并发症。在本研究的大多数病例中，使用维替泊芬的光动力疗法对角膜新生血管的治疗是有效的。
To investigate the efficacy of photodynamic therapy (PDT) with verteporfin for the treatment of patients with corneal neovascularization. Retrospective interventional case series of 33 eyes of 32 patients with stable corneal neovascularization who were refractory to conventional treatment and were treated with single photodynamic therapy with verteporfin (6 mg/m2) at King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia between January 1, 2007 and December 30, 2009. The mean age was 40.7 ± 19 years (range 16-76 years). The mean follow-up for all patients was 13.1 ± 5.5 months (range 6-24 months). The average amount of corneal neovascularization was 2.7 ± 1.9 (1-10). Corneal neovascularization was deep in 19 (57.6%) eyes and superficial in 14 (42.4%) eyes. Preoperative and postoperative visual acuity and intraocular pressure, and clinical outcome of the treatment were assessed. Statistical analysis was performed to investigate the association to potential risk factors, to assess the change in data and determine the risks for failure. A P-value less than 0.05 was statistically significant. At the last follow-up visit, 22 (66.7%) eyes showed a decrease in corneal neovascularization and evidence of vascular thrombosis. Complete vascular occlusion was achieved in 14 (42.4%) eyes, partial occlusion was achieved in 8 (24.2%) eyes, and the vessels were patent in 11 (33.3%) eyes. The corneal neovascularization score and depth of the vessels were found to be significant risk factors for failure (P = 0.0001 and 0.046, respectively). However, the diagnoses or causes of corneal neovascularisation were not statistically significant. No significant systemic or ocular complications associated with photodynamic therapy were observed. Photodynamic therapy with verteporfin was effective for the treatment of corneal neovascularization in the majority of the cases in this study.